Description
Medtronic Doubles Down on Innovation as Cardiovascular Tech Takes Center Stage!
Medtronic’s fourth-quarter results for fiscal year 2025 demonstrated a robust finish with a reported revenue growth of 5.4%. The company experienced strong performance across its cardiovascular, neuromodulation, and diabetes segments, with cardiovascular growth accelerating to 8% due to innovations in pulse field ablation and cardiac ablation solutions experiencing nearly 30% growth. This momentum was further supported by double digit growth in neuromodulation and diabetes, highlighting the effectiveness of Medtronic’s innovation-centric strategy.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
